Walleye Capital
IMNM icon

Walleye Capital’s Immunome IMNM Stock Holding History

Walleye Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-111,183
Closed -$2.43M – 4939
2026
Q1 		$2.43M Buy
+111,183
New +$2.47M 0.01% 1321
2025
Q2 		– Sell
-37,114
Closed -$250K – 4739
2025
Q1 		$250K Buy
+37,114
New +$356K ﹤0.01% 3097
2024
Q3 		– Sell
-25,457
Closed -$308K – 5555
2024
Q2 		$308K Buy
+25,457
New +$398K ﹤0.01% 3953

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Walleye Capital's IMNM Position: Q2 2026 in Review

Walleye Capital sold out of Immunome (IMNM) in Q2 2026, closing a stake of 111,183 shares — an estimated $2.43M sold.

Walleye Capital first reported a position in IMNM in Q2 2024 and held it in 3 quarters. The position peaked at $2.43M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Walleye Capital reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 111,183 Immunome shares in Q2 2026, an estimated $2.43M.
  • Walleye Capital first reported a position in Immunome in Q2 2024 and held it in 3 quarters.
  • Walleye Capital's Immunome position peaked at $2.43M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.